Pieris Pharmaceuticals (DE:PI60)
FRANKFURT:PI60
Holding DE:PI60?
Track your performance easily

Pieris Pharmaceuticals (PI60) Income Statement

0 Followers

Pieris Pharmaceuticals Income Statement

Last quarter (Q3 2023), Pieris Pharmaceuticals's total revenue was $19.52M, an increase of 263.50% from the same quarter last year. In Q3, Pieris Pharmaceuticals's net income was $-10.75M. See Pieris Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 22Dec 21Dec 20Dec 19Dec 18
Total Revenue
$ 49.05M$ 25.90M$ 3.69M$ 29.32M$ 46.28M$ 29.10M
Cost of Revenue
------
Gross Profit
$ 48.97M$ 25.90M$ 3.69M---
Operating Expense
$ 14.51M$ 69.38M$ 83.25M$ 63.24M$ 73.44M$ 59.93M
Operating Income
$ -8.05M$ -43.47M$ -79.56M$ -33.92M$ -27.16M$ -30.83M
Net Non Operating Interest Income Expense
$ 279.00K$ 721.00K$ 4.00K$ 511.00K$ 1.71M$ 1.96M
Other Income Expense
$ -19.84M$ -9.91M$ -33.82M$ -3.66M$ -26.00K$ 1.80M
Pretax Income
$ 8.12M$ -33.28M$ -45.74M$ -37.07M$ -25.47M$ -27.07M
Tax Provision
---$ 164.00K$ 0.00$ -312.00K
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ 4.80M$ -33.28M$ -45.74M$ -37.23M$ -28.30M$ -26.75M
Basic EPS
---$ -0.68$ -0.56$ -0.50
Diluted EPS
---$ -0.68$ -0.56$ -0.50
Basic Average Shares
---$ 54.48M$ 50.63M$ 53.08M
Diluted Average Shares
---$ 54.48M$ 50.63M$ 53.08M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 14.51M$ 69.38M$ 83.25M$ 63.24M$ 73.44M$ 59.93M
Net Income From Continuing And Discontinued Operation
$ -28.06M$ -33.28M$ -45.74M$ -37.23M$ -25.47M$ -26.75M
Normalized Income
$ 9.54M$ -26.29M-$ -37.23M$ -25.47M$ -26.75M
Interest Expense
------
EBIT
$ 9.24M$ -33.28M$ -45.74M$ -33.92M$ -27.16M$ -30.83M
EBITDA
$ 11.91M$ -30.51M$ -43.28M$ -31.79M$ -26.12M$ -30.26M
Currency in USD

Pieris Pharmaceuticals Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis